Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer, M.D., has been named Omeros’ chief medical officer. In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical development and operations, medical affairs, safety, and biometrics. A highly tenured physician, scientist and pharmaceutical leader, Dr. Grauer brings to Omeros over 20 years of industry experience across a broad range of therapeutic areas including inflammation, nephrology, oncology, neurology, endocrinology, and metabolism.

“We are very pleased to welcome Andreas to Omeros’ leadership team,” said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. “Andreas brings tremendous depth and breadth of clinical leadership expertise, a proven track record of worldwide BLA and NDA approvals, and a strategic approach to pipeline and product development that includes successful management of complex global alliances. I am confident that Andreas will deliver for our organization as we seek to maximize the value of our extensive development pipeline.”

With more than two decades overseeing development programs spanning phases 1b, 2, 3, and 4, resulting in multiple BLA and NDA approvals in US, Canada, Europe, and Japan as well as lifecycle management, Dr. Grauer has served in leadership roles at both large and small biopharmaceutical companies. He joins Omeros from Federation Bio where, as chief medical officer, he led all clinical activities with a focus on hyperoxaluria and immuno-oncology. Prior to that, Dr. Grauer was chief medical officer at Corcept Therapeutics, leading its global development organization in the design and execution of phase 1 through phase 3 clinical programs in oncology, neurology, endocrinology, and metabolism indications. Before his time at Corcept, Dr. Grauer held several roles of increasing responsibility at Amgen, most recently serving as vice president of global development, therapeutic area head, and co-chair of the franchise steering committee for bone, nephrology and inflammation. While in that role, he was responsible for franchise strategy and four global filings across multiple therapeutic areas. Earlier in his career, Dr. Grauer was at Proctor and Gamble Pharmaceuticals where he held roles as global executive medical director for bone and for new technology development.

“I am excited to join the leadership team at Omeros,” said Dr. Grauer. “The strength of the team, together with our leading franchise of complement inhibitors in late-stage development and innovative earlier-stage assets, present outstanding opportunities to improve the lives of patients while delivering significant value for shareholders. I look forward to leading Omeros’ clinical development efforts and to contributing to the Company’s success.”

Dr. Grauer received his medical degree from the University of Heidelberg Medical School, Germany, where he also completed his medical training in internal medicine and endocrinology. He did research in molecular and cellular endocrinology both there and during a post-doctoral fellowship at Baylor College of Medicine. He holds an active associate professorship of medicine at the University of Heidelberg Medical School and has authored over 120 publications in top-tier journals.

About Omeros Corporation

Omeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. Omeros’ lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including COVID-19. Omeros’ long-acting MASP-2 inhibitor OMS1029 is currently in a Phase 1 clinical trial. OMS906, Omeros’ inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing across multiple clinical programs for alternative pathway-related diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and complement 3 (C3) glomerulopathy. For more information about Omeros and its programs, visit www.omeros.com.

Forward-Looking Statements

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, these statements are often identified by the words “may”, “might”, “believes”, “thinks”, “anticipates”, “plans”, “expects”, “intends” or similar expressions. These forward-looking statements include, but are not limited to, expectations regarding the performance and anticipated contributions of newly-hired personnel. Such forward-looking statements are based on current information available to the Company and involve inherent risks and uncertainties, including factors that could delay, divert or change any such forward-looking statements, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. In addition, such risks and uncertainties may include those described in the Company’s annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC, which are available at the Company’s website (www.omeros.com) under “Investors & News”. You are cautioned not to place undue reliance on any forward-looking statements as there are important factors that could cause actual results to differ materially from those in any forward-looking statements, many of which are beyond our control. Except to the extent required by law, the Company undertakes no obligation to publicly update any forward-looking statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231019539719/en/